APA način citiranja

Martin, A., & Schellenberg, R. (2012). Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients. BioMed Central.

Čikaški stil citiranja

Martin, Adriana, i Robert Schellenberg. Evaluation of Safety and Efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), After a Dose Equivalent Switch From Intravenous or Subcutaneous Replacement Therapy in a Cohort of Primary Immunodeficient Patients. BioMed Central, 2012.

MLA način citiranja

Martin, Adriana, i Robert Schellenberg. Evaluation of Safety and Efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), After a Dose Equivalent Switch From Intravenous or Subcutaneous Replacement Therapy in a Cohort of Primary Immunodeficient Patients. BioMed Central, 2012.